RSS   Newsletter   Contact   Advertise with us

Faron Pharma appoints two directors

Staff Writer | Turku, Finland | April 20, 2017
Faron PharmaApril 20, 2017, Turku, Finland - Faron Pharmaceuticals, a clinical stage biopharmaceutical company, announced the proposed appointment of two new non-executive directors Gregory B. Brown and John Poulos, to the company's board.
Gregory B. Brown has more than 35 years of experience in healthcare and investment.

Most recently, Dr. Brown founded HealthCare Royalty Partners, a healthcare-focused private asset management firm investing in biopharmaceutical and medical products, where he currently serves as Vice Chairman.

In addition, Dr. Brown is currently a director of Caladrius Biosciences Inc and Nuron Biotech Inc and previously acted as a director of Invuity Inc between October 2014 and December 2015.

Prior to this, Dr. Brown was a General Partner at Paul Capital Partners in New York, Co-Head of Investment Banking at Adams, Harkness & Hill, and VP of Corporate Finance at Vector Securities International.

John Poulos has a wealth of expertise in global corporate life sciences, having spent 38 years working for AbbVie and Abbott.

Most recently, Mr. Poulos served as Vice President, Head of Licensing and Acquisitions for AbbVie, and Group Vice President, Head of Pharmaceutical Licensing and Acquisitions for Abbott Pharmaceuticals.

During his career, Mr. Poulos was instrumental in the negotiation of numerous acquisitions, including Knoll/BASF Pharma in 2001 and Solvay in 2010.